Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Amylyx Pharmaceuticals Inc (AMLX)
NASDAQ:AMLX
RESEARCH TOOLSreports
Amylyx Pharmaceuticals Inc (AMLX) Stock Price & Analysis
459 Followers
AMLX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.58 - $25.48
Previous Close$2.02
Volume968.18K
Average Volume (3M)1.96M
Market Cap
$137.37M
Enterprise Value-$232.23M
Total Cash (Recent Filing)$373.29M
Total Debt (Recent Filing)$3.69M
Price to Earnings (P/E)―
Beta1.80
Next Earnings
Aug 08, 2024EPS Estimate
-$0.73Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.07
Shares Outstanding68,005,749
10 Day Avg. Volume1,339,036
30 Day Avg. Volume1,955,859
Standard Deviation0.35
R-Squared0.01
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)0.28
Price to Sales (P/S)1.37
Price to Cash Flow (P/CF)2.20
P/FCF Ratio2.30
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-0.58
Enterprise Value/Gross Profit-0.65
Enterprise Value/Ebitda2.33
Forecast
1Y Price Target
$4.63Price Target Upside129.21% Upside
Rating ConsensusHold
Number of Analyst Covering6
Amylyx Pharmaceuticals Inc News
Bulls Say, Bears Say
Bulls Say
AcquisitionThe acquisition of phase 3 ready avexitide is viewed as a positive value add for Amylyx.
Financial PositionAmylyx ended 1Q24 with cash and equivalents of $373M which the company expects provides cash runway into 2026 for anticipated data readouts.
Market OpportunityWith AMLX estimating approximately 160K addressable US patients with post-bariatric hypoglycemia and no currently approved therapies, the revenue opportunity could be sizable.
Bears Say
Company StatusAmylyx's brief stint as a commercial biotech company has come to a close, and the company is now once again clinical stage.
Market OpportunityMuch remains to be understood regarding the market opportunity, including in the context of GLP-1RAs and other anti-obesity medications which may disrupt the rate of bariatric surgeries over the medium to long-term.
Pipeline ClarityMore clarity is needed on the rest of the company's pipeline before the stock would trade meaningfully above a zero enterprise value.
---
Ownership Overview
46.06% Insiders
21.70% Mutual Funds
8.81% Other Institutional Investors
23.43% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AMLX FAQ
What was Amylyx Pharmaceuticals Inc’s price range in the past 12 months?
Amylyx Pharmaceuticals Inc lowest stock price was $1.57 and its highest was $25.48 in the past 12 months.
What is Amylyx Pharmaceuticals Inc’s market cap?
Currently, no data Available
When is Amylyx Pharmaceuticals Inc’s upcoming earnings report date?
Amylyx Pharmaceuticals Inc’s upcoming earnings report date is Aug 08, 2024 which is in 19 days.
How were Amylyx Pharmaceuticals Inc’s earnings last quarter?
Amylyx Pharmaceuticals Inc released its earnings results on May 09, 2024. The company reported -$1.75 earnings per share for the quarter, missing the consensus estimate of -$0.004 by -$1.746.
Is Amylyx Pharmaceuticals Inc overvalued?
According to Wall Street analysts Amylyx Pharmaceuticals Inc’s price is currently Undervalued.
Does Amylyx Pharmaceuticals Inc pay dividends?
Amylyx Pharmaceuticals Inc does not currently pay dividends.
What is Amylyx Pharmaceuticals Inc’s EPS estimate?
Amylyx Pharmaceuticals Inc’s EPS estimate is -$0.73.
How many shares outstanding does Amylyx Pharmaceuticals Inc have?
Amylyx Pharmaceuticals Inc has 68,005,750 shares outstanding.
What happened to Amylyx Pharmaceuticals Inc’s price movement after its last earnings report?
Amylyx Pharmaceuticals Inc reported an EPS of -$1.75 in its last earnings report, missing expectations of -$0.004. Following the earnings report the stock price went down -2.073%.
Which hedge fund is a major shareholder of Amylyx Pharmaceuticals Inc?
Among the largest hedge funds holding Amylyx Pharmaceuticals Inc’s share is Farallon Capital Management, L.L.C.. It holds Amylyx Pharmaceuticals Inc’s shares valued at 3M.
---
Amylyx Pharmaceuticals Inc Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$4.63 (129.21% Upside)
$4.63 (129.21% Upside)
Blogger Sentiment
Bullish
AMLX Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 4.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $9.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.5%
Last 30 Days ▼ 1.4%
Last 30 Days ▼ 1.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-90.87%
12-Months-Change
Fundamentals
Return on Equity
-21.00%
Trailing 12-Months
Asset Growth
2.33%
Trailing 12-Months
Company Description
Amylyx Pharmaceuticals Inc
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases.
---
AMLX Earnings Call
Q1 2024
0:00 / 0:00
---
AMLX Stock 12 Month Forecast
Average Price Target
$4.63
▲(129.21% Upside)
Technical Analysis
Best Analysts Covering AMLX
1 Year
1 Year Success Rate
3/17 ratings generated profit
1 Year Average Return
-43.74%
reiterated a buy rating 11 days ago
Copying Andrew Fein's trades and holding each position for 1 Year would result in 17.65% of your transactions generating a profit, with an average return of -43.74% per trade.
---